IGFBP3 and neoplasm: Lower n-6:n-3 ratio in intervention for benign and malignant prostate tissue and RBCs (p = 0.042, p < 0.001, and p < 0.001, respectively); reduced tumor proliferation rate (Ki67) in intervention (p = 0.026); no difference between groups for serum IGF-1, IGFBP-1, IGFBP-3, PSA, urine PGEM, or prostatic prostaglandin E2, COX-2, angiogenesis (CD31), or apoptosis (TUNEL)